Bengaluru-based biopharma company PlasmaGen Biosciences has secured Rs 150 crore in a new funding round led by ViNS Bioproducts. The round also saw participation from high-net-worth individuals, family offices, pharmaceutical entrepreneurs, and existing investors. Following this infusion, the company is valued at over Rs 1,500 crore, underscoring strong investor confidence in its business model and long-term vision.
The funding comes at a time when interest is rising in companies that address critical healthcare gaps through domestic manufacturing. PlasmaGen’s focus on plasma-derived medicines places it in a niche but essential segment of the biopharmaceutical industry.
A Decade-Long Journey Backed by Global Investors
With this latest round, PlasmaGen has raised more than Rs 600 crore in funding since its inception. Over the years, it has attracted backing from well-known investors including Fidelity’s FIL Capital Investments, Eight Roads Ventures, and F-Prime Capital. This consistent institutional support has helped the company build large-scale infrastructure and develop capabilities required for a highly regulated business.
PlasmaGen is backed by Eight Roads Ventures, and its ability to raise capital repeatedly reflects growing belief in its execution and focus on long-term value creation rather than quick wins.
Clear Plans for Using the New Capital
The company said the newly raised funds will be used to scale its international operations, expand its product portfolio, and strengthen manufacturing as well as leadership capabilities. These investments are expected to support PlasmaGen’s transition from a largely India-focused player to one preparing for global markets.
Founded in 2010 by Vinod Nahar, PlasmaGen Biosciences focuses on building domestic capabilities in plasma-derived therapies to reduce India’s dependence on imports.
Strengthening leadership and operational depth is also a priority, as plasma-derived therapies require strict quality controls, compliance with regulations, and specialized expertise across production and distribution.
Addressing India’s Plasma Medicine Gap
Founded in 2010, PlasmaGen Biosciences is focused on developing and commercializing plasma-derived therapies such as Immunoglobulin, Albumin, and clotting factors. These medicines play a vital role in treating neurological disorders, blood-related conditions, and patients in critical care.
India has historically faced a shortage of plasma-derived products, leading to heavy reliance on imports. PlasmaGen aims to narrow this gap by building domestic capacity and ensuring a steady supply of essential therapies. The company positions its work as part of a broader effort to improve access to life-saving medicines within the country.
Also Read: Muuchstac: The Relentless Focus Behind a ₹450-Crore Acquisition
Modern Manufacturing Hub Near Bengaluru
At the heart of PlasmaGen’s operations is its plasma fractionation facility in Kolar, Karnataka, located near Bengaluru. The company began commercial operations at this plant in 2024. PlasmaGen states that the facility is among only five such plasma fractionation units currently operating in India.
Designed to meet stringent quality and safety requirements, the Kolar facility represents a major investment in local manufacturing. Since the start of commercial operations, the company reports strong revenue growth, driven by rising demand from hospitals and healthcare providers.
Steady Expansion Across Hospitals and Doctors
While international expansion is a key goal, India continues to remain a core market for PlasmaGen. The company is expanding its reach across hospitals and physicians through a cold-chain-supported distribution network. Maintaining temperature control is essential for plasma-derived therapies, and this infrastructure plays a critical role in ensuring product safety and effectiveness.
By strengthening its domestic distribution, PlasmaGen aims to deepen relationships with healthcare providers and improve access to its therapies across regions.
Laying the Groundwork for Overseas Markets
PlasmaGen has identified distribution partners in several key export markets and is currently working to secure the regulatory approvals required to begin international sales. These steps mark an important phase in the company’s growth as it prepares to take its products beyond India.
The move into global markets is expected to complement its domestic presence rather than replace it, allowing the company to balance growth opportunities while continuing to serve Indian patients.
Focused Identity in a Specialized Sector
PlasmaGen positions itself as India’s first pure-play plasma biopharma company. It is entirely focused on plasma-derived products. The company is differentiating itself in a complex and tightly regulated industry by leveraging specialized manufacturing, an expanding product portfolio, and global expansion plans.
PlasmaGen is going to the next level, manufacturing base in Karnataka is its core of development and at the same time, globally the company is getting ready to serve markets, however, most of its activities are still healthcare-related.
Also Read: Symbiotics Backs Dugar Finance With $18 Million Debt Infusion
